A phase II study of buparlisib in relapsed or refractory thymomas.

ABSTRACT:

Purpose

To investigate the efficacy and safety of buparlisib, an oral pan-PI3K inhibitor, in relapsed or refractory thymomas.

Methods

This was a single center, single arm, open label phase II trial of buparlisib in patients with recurrent thymoma who have progressed after at least one prior line of treatment. The primary endpoint was objective response rate (complete response [CR] + partial response [PR]). Secondary endpoints included toxicity; progression free survival (PFS); overall survival (OS); disease control rate (DCR), i.e., the percentage of patients who achieve either PR or CR or stable disease [SD] for at least 4 months.

Results

Between 10/13/2014 and 1/18/2017, 14 patients with stage IV disease were enrolled. Median age was 58y (23-74). 71% were females an

SUBMITTER: Abu Zaid MI 

PROVIDER: S-EPMC9623263 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature